glp 1 agonist vs sglt2 inhibitor Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study Blood Pressure-Lowering Effects of SGLT2

Graphical abstract Similar content being viewed by others Introduction Tirzepatide (LY3298176) is the first peptide dual agonist for type 2 diabetes mellitus (T2DM), which targets both GIPR and GLP1R

GLP-1 medications work biologically to reset appetite and satiety, making the weight loss achievable and sustainable as long as the medication is continued

Recent Prog Horm Res (1975) 31:487532

Metabolic health improved

The purpose of this review is to compare the clinical trial and real-world effectiveness data of second-line therapy with SGLT2-I and GLP-1RA related to A1c reduction, weight loss, cost-effectiveness, and safety in patients with T2DM

The participants taking semaglutide had a Both trials show that oral semaglutide is very effective for weight loss when used in conjunction with a reduced-calorie diet and exercise